To test whether INHBA is both necessary and sufficient to confer ICB resistance, we administered anti-PD1/anti-CTLA4 ICB therapy or IgG control antibodies to YUMM3.3-Ctrl and -βΑ tumor grafts. Here, CTLA4 is linked to neoplasm.